Stock comparison
Genmab A/S
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 72B | LLY |
| Benjamin Graham | 64C | 86A | LLY |
| Philip Fisher | 48D | 86A | LLY |
| Peter Lynch | 25F | 74B | LLY |
| Joel Greenblatt | 76B | 78C | LLY |
| Charlie Munger | 68C | 85A | LLY |
| Terry Smith | 71C | 77C | LLY |
Side-by-side metrics
| Metric | GMAB | LLY |
|---|---|---|
| Market cap | $16.5B | $1T |
| P/E (TTM) | 6.2x | 36.6x |
| EV/EBIT | 12.0x | 34.1x |
| ROIC (TTM) | 43.78% | 32.06% |
| Gross margin | 93.88% | 83.51% |
| Net margin | 18.23% | 34.98% |
| Revenue CAGR 5y | -18.45% | 23.17% |
| EPS CAGR 5y | -23.48% | 40.81% |
| Debt / Equity | 0.1x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.4x+95%
- P/E (TTM)6.2xvs 36.6x+83%
- EV/EBIT12.0xvs 34.1x+65%
- ROIC (TTM)43.78%vs 32.06%+27%
LLY leads on
- Revenue CAGR 5y23.17%vs -18.45%+180%
- EPS CAGR 5y40.81%vs -23.48%+158%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $16.5B+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.